Analysis of the threedimensional accelerating flow in a mixed turbine rotor

An investigation on new rotor blade designs conceived to produce higher exit relative kinetic energy of a mixed flow turbine is undertaken. Accelerating the flow through the rotor in a relative frame of reference improves energy transfer to the shaft, which is only produced in a rotating rotor. A three-dimensional converging rotor channel might respond to the analysis requirements in the subsonic flow regimes. Effectively, the machine experiences a 3.71 % and 3.67 % increase in work output and efficiency, respectively, representing this study’s primary intent. This has been accomplished by varying the shroud profile to a lesser eye tip diameter, then the hub profile to a larger eye root diameter. At last, both shroud and hub profiles are varied. It appears possible to enhance the performance of the rotor in terms of optimum work done and efficiency by devising suitable blade geometry designs. ANSYS CFX 15 is the code of all simulation works

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.

Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease; its management is largely empirical. This is the first clinical study to determine if interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option in AOSD. In this phase II, open-label study, patients were ≥18 years with active AOSD plus fever or C reactive protein (CRP) levels ≥10 mg/L despite treatment with prednisone and/or conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Previous biological DMARD treatment was permitted. Patients received tadekinig alfa 80 mg or 160 mg subcutaneously three times per week for 12 weeks; those receiving 80 mg not achieving early predicted response criteria (reduction of ≥50% CRP values from baseline and fever resolution) were up-titrated to 160 mg for a further 12 weeks. The primary endpoint was the occurrence of adverse events (AEs) throughout the study. Ten patients were assigned to receive 80 mg tadekinig alfa and 13 patients to the 160 mg dose. One hundred and fifty-five treatment-emerging AEs were recorded, and 47 were considered related to the study drug. Most AEs were mild and resolved after drug discontinuation. Three serious AEs occurred, one possibly related to treatment (toxic optic neuropathy). At week 3, 5 of 10 patients receiving 80 mg and 6 of 12 patients receiving 160 mg achieved the predefined response criteria. Our results indicate that tadekinig alfa appears to have a favourable safety profile and is associated with early signs of efficacy in patients with AOSD. NCT02398435

HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4-16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS

Game Dynamics and Cost of Learning in Heterogeneous 4G Networks

International audienceIn this paper, we study game dynamics and learning schemes for heterogeneous 4G networks. We introduce a novel learning scheme called cost-to-learn that incorporates the cost to switch, the switching delay, and the cost of changing to a new action and, captures the realistic behavior of the users that we have experimented on OPNET simulations. Considering a dynamic and uncertain environment where the users and operators have only a numerical value of their own payoffs as information, we construct various heterogeneous combined fully distributed payoff and strategy reinforcement learning (CODIPAS-RL): the users try to learn their own optimal payoff and their optimal strategy simultaneously. We establish the asymptotic pseudo-trajectories as solution of differential equations. Using evolutionary game dynamics, we prove the convergence and stability properties in specific classes of dynamic robust games. We provide various numerical examples and OPNET simulations in the context network selection in wireless local area networks (WLAN) and Long Term Evolution (LTE)

Evolutionary Coalitional Games: Design and Challenges in Wireless Networks

International audienceThe current state of the art of evolutionary coalitional game theory in wireless networking and communications is captured in this article, where solutions are discussed under their related applications. Fully distributed algorithms for global optima in network selection games are examined. Then the problem of dynamic network formation and evolutionary coalitional games in wireless networks are investigated. This article also points out the open research issues, new interests, and developments in this interdisciplinary field

Dynamic Power Control with Energy Constraint for Multimedia Wireless Sensor Networks

International audienceIn recent years, many approaches and techniques have been explored for the optimization of energy usage in Wireless Sensor Networks (WSN). It is well recognized that a proper energy consumption model is the foundation for developing and evaluating a power management scheme in WSN. In this paper, we propose a new complete information Markov Decision Process (MDP) model to characterize sensors energy levels. We also propose and compare several centralized power control policies to select the more efficient policy that optimizes throughput and energy consumption

High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study.

Hypofractionated stereotactic radiation therapy (HSRT) for vertebral metastases gives good results in terms of local control but increases the risk of fracture in the treated volume. Preclinical and clinical studies have shown that zoledronate not only reduces the risk of fracture and stimulates osteoclastic remodeling but also increases the immune response and radiosensitivity. This study aimed to evaluate the tolerability and effectiveness of zoledronate in association with radiation therapy. We conducted a multicenter phase 1 study that combined HSRT (3 × 9 Gy) and zoledronate in patients with vertebral metastasis (NCT01219790). The principal objective was the absence of spinal cord adverse reactions at 1 year. The secondary objectives were acute tolerability, the presentation of a bone event, local tumor control, pain control, progression-free survival, and overall survival. Thirty patients (25 male, 5 female), median age 66 years, who were followed up for a median period of 19.2 months, received treatment for 49 vertebral metastases. A grade 3 acute mucosal adverse event occurred in 1 patient during the treatment and in 2 more at 1 month. No late neurologic adverse events were reported at 1 year. The mean pain scores diminished significantly at 1 month (1.35; P=.0125) and 3 months (0.77; P<.0001) compared with pain scores at study entry (2.49). Vertebral collapse in the irradiated zone occurred in 1 (2%) treated vertebra. Control of local disease was achieved in 94% of irradiated patients (3 local recurrences). The combination of zoledronate and HSRT in the treatment of vertebral metastasis is well tolerated and seems to reduce the rate of vertebral collapse, effectively relieve pain, and achieve good local tumor control with no late neurologic adverse effects

Virgibacillus doumboii sp. nov., a halophilic bacterium isolated from the stool of a healthy child in Mali

International audienc